Hansa Biopharma (HNSA) Corporate presentation summary

Innovative IgG-cleaving enzyme platform

• Proprietary enzymes imlifidase and HNSA-5487 enable rapid, targeted IgG reduction, addressing barriers in transplantation, gene therapy, and autoimmune diseases.

• Imlifidase achieves >95% IgG reduction in 2-6 hours and is supported by 11 clinical programs.

• HNSA-5487, a next-generation enzyme, targets Guillain-Barré Syndrome (GBS) with FDA interactions planned for 2026.

Transplantation: addressing high unmet need

• Imlifidase (Idefirix) is conditionally approved in Europe for desensitization prior to kidney transplantation; US PDUFA date set for December 2026.

• Over 200 highly sensitized patients treated; market opportunity exceeds $2bn in Europe and the US.

• US Confides Phase 3 study showed significant improvement in kidney function and reduced dialysis dependency.

• Long-term follow-up shows 82% five-year graft survival and 90% patient survival.

Commercialization and partnerships

• €115 million licensing agreement with SERB Pharma for Idefirix in Europe and MENA, with €110M upfront and €5M upon EMA filing acceptance.

• Transaction improves cash position to ~1.9 BSEK and reduces cost base, supporting profitability.

• Robust US commercialization strategy with experienced team and focused market access initiatives.